The 'Indian strain' of the coronavirus, also known as B.1.617 or a 'double mutant', has been found in at least 17 countries, the WHO has said, as the world grapples to contain the surge in the COVID-19 cases with 5.7 million infections detected last week, surpassing previous peaks.
The B.1.617 variant of SARS-CoV2 or the 'Indian strain’, feared to be contributing to a surge in coronavirus cases in India, has been designated as the Variants of Interest (VOI) by the World Health Organisation (WHO), the UN health agency said in its weekly epidemiological update on Tuesday.
"As of 27 April, over 1,200 sequences have been uploaded to GISAID and assigned to lineage B.1.617 (collectively) from at least 17 countries,” it said, adding that most sequences were uploaded from India, the United Kingdom, USA and Singapore.
GISAID is a global science initiative and primary source established in 2008 that provides open-access to genomic data of influenza viruses and the coronavirus responsible for the COVID-19 pandemic.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
"Emerging SARS-CoV-2 variants within Pango lineage B.1.617 were recently reported as a VOI from India and have recently been designated as VOIs by WHO,” it said.
The WHO said that studies have highlighted that the spread of the second wave has been much faster than the first in India.
"Preliminary modelling by WHO based on sequences submitted to GISAID suggest that B.1.617 has a higher growth rate than other circulating variants in India, suggesting potential increased transmissibility, with other co-circulating variants also demonstrating increased transmissibility,” the report by the global health body said.
"Other drivers may include challenges around the implementation and adherence to public health and social measures (PHSM), and social gatherings (including mass gatherings during cultural and religious celebrations, and elections). Further investigation is needed to understand the relative contribution of these factors,” it said.
In many cities in Maharashtra – the worst-hit state in India – the B.1.617 variant was found in more than 50 percent of samples on which genome sequencing was conducted, Sujeet Singh, the Director of the National Centre for Disease Control, had said in a webinar on genome sequencing last week.
The B.1.617 variant comprises several sub-lineages, including B.1.617.1, B.1.617.2 and B.1.617.3, which slightly differ by their characteristic mutations, the WHO report said.
Both B.1.617.1 and B.1.617.2 were first identified in India in December 2020, and have been detected at increasing prevalence concurrent to the major upsurge observed in the country.
B.1.617.3 was first detected in India in October 2020, but relatively fewer viruses matching this sub-lineage have been reported to date, the report said.
The B.1.617 variant has three new spike protein mutations.
Two mutations — E484Q and L452R — are in the area important for antibody-based neutralisation. The third mutation — P681R — allows the virus to enter cells a little better. These are defining characteristics of the variant.
The third mutation — P681R — allows the virus to enter cells a little better.
These are defining characteristics of the variant. Covishield and Covaxin – the two coronavirus vaccines currently in use in India – have efficacy against the 'Indian strain’ and show "milder" illness in case of infection post vaccination, Anurag Agrawal, the Director of the Institute of Genomics and Integrative Biology (IGIB), said, citing preliminary results of a study.
The WHO said that globally, new COVID-19 cases increased for the ninth consecutive week, with nearly 5.7 million new cases reported in the last week, surpassing previous peaks and India accounts for 38 percent of the global cases reported during the period.
The number of new deaths increased for the sixth consecutive week, with over 87,000 new deaths reported.
For the third consecutive week, the South-East Asia region reported the highest relative increases in both case and death incidences.
"While a number of countries in the region are reporting upward trends, India accounts for the vast majority of cases from this regional trend and 38 percent of global cases reported in the past week,” it said.
With 52 percent increase, India has reported the highest number of new cases (21,72,063) followed by the US (406,001 new cases; 15 percent decrease), Brazil (404,623 new cases; 12 percent decrease), Turkey (378,771 new cases; 9 percent decrease), and France (211,674 new cases; 9 percent decrease).Follow our full coverage of the coronavirus pandemic here.